Grey Wolf Therapeutics
PrivateLast Round
Series B
Extension
May 23, 2024
Total Funding Raised
$118.37M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Grey Wolf Therapeutics operates in Healthcare & Life Sciences and is based in Abingdon. Its latest recorded funding round was a Series B Extension round in May 2024.
Grey Wolf Therapeutics is a biotechnology company that develops novel antigen modulation therapies to treat cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Grey Wolf Therapeutics Comparables
Compare Grey Wolf Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeoPhore | 81% | |
| Enara Bio | 74% | |
| Pathios Therapeutics | 73% |
For institutional investors. Book with your work email.
Grey Wolf Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 23, 2024 | ||||
| Series B | Jan 26, 2023 | ||||
| Grant | May 18, 2021 | ||||
| Series A Extension | Jan 9, 2020 | ||||
| Series A | Feb 11, 2019 | ||||
Seed | Sep 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Grey Wolf Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andera Partners | Series B, Series A Extension, Series A, Series B Extension |
| Oxford Science Enterprises | Series B, Series B Extension |
| Intermediate Capital Group | Series B Extension |
| British Patient Capital | Series B, Series B Extension |
| Innovate UK | Grant |
| Canaan Partners | Series B, Series A Extension, Series B Extension, Series A |
| Oxford Science Enterprises | Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 66% MoM.
- Aug 22, 2026
Monthly visitors increased 66% MoM, reaching 2K.
For institutional investors. Book with your work email.
Grey Wolf Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Grey Wolf Therapeutics's valuation, stock price, and market status.
Is Grey Wolf Therapeutics a public or private company?
Grey Wolf Therapeutics is a private company.
What is the current stock price of Grey Wolf Therapeutics?
Grey Wolf Therapeutics is a private company, so its shares have no public market price. Caplight tracks Grey Wolf Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Grey Wolf Therapeutics worth (valuation)?
Valuation information for Grey Wolf Therapeutics is not publicly available.
Can I buy Grey Wolf Therapeutics stock?
Grey Wolf Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Grey Wolf Therapeutics's last funding round?
Grey Wolf Therapeutics's most recent funding round was Series B Extension on May 23, 2024.
Who are the main investors in Grey Wolf Therapeutics?
Key investors in Grey Wolf Therapeutics include Intermediate Capital Group, Canaan Partners, Pfizer Ventures, Earlybird Venture Capital, Pfizer.
Will Grey Wolf Therapeutics IPO soon?
No public IPO plans have been announced for Grey Wolf Therapeutics.
How can I track Grey Wolf Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Grey Wolf Therapeutics's shares on secondary markets.